 |
 |
Thankyou Linda, for the headsup on the KW-6002 study... Apparently this is going on in several centers.... Mass. and Ohio and Colorado and Maryland and Quebec ..... For more info read.... http://clinicalstudies.info.nih.gov/detail/A_2001-N-0001.html http://www.centerwatch.com/patient/studies/stu20281.html http://www.ulaval.ca/vrr/rech/Cherc/23742.html http://www-neuro.med.ohio-state.edu/parkinsons/index.html http://www.thecni.org/recruitment.htm http://www.thecni.org/recruitment.htm#Exploratory Study http://link.springer- ny.com/link/service/journals/00213/bibs/9147001/91470090.htm Best regards ...... murray On 13 Jan 2001, at 5:54, Linda J Herman wrote: > I recently subscribed to Centerwatch - an email notification service > about new clincial trials. The following was received today. There is > more info on it, describing in detail what is involved in the study, > criteria for selection at: > http://www.centerwatch.com/studies/stu23624.htm and other ongoing > trials listed on their web site: www.centerwatch.com Linda Herman > > --------- Forwarded message ---------- > Date: Sat, 13 Jan 2001 08:10:48 (GMT) > Subject: CW Patient Notification > This email is being sent to notify you that the following new clinical > trial(s) in your selected area of interest have been recently posted on > the CenterWatch web site at http://www.centerwatch.com. > > 1) Adenosine A2A Blockade with KW-6002 in Parkinson's Disease. This > study is being conducted in: > - Bethesda, MD (http://www.centerwatch.com/studies/stu23624.htm) > This study will evaluate the effects of an experimental drug called > KW-6002 on Parkinson's disease symptoms and on dyskinesias (involuntary > movements) that develop as a result of long-term treatment with > levodopa. This drug blocks the action of the neurotransmitter adenosine, > thought to be involved in producing Parkinson's symptoms. > --------------------------------------------------------- ******** [log in to unmask]